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mavadani@yahoo.cAbstract The fruits of Piper cubeba have been used in Ayurvedic system of medicine for pain,
tastelessness, painful urination and mouth diseases. Among its various chemical constituents,
(-)-hinokinin, a trypanosomicidal dibenzylbutyrolactone lignan, is found in signiﬁcant quantities.
For quality evaluation of P. cubeba fruit and its commercial formulations, there is an urgent need
to develop an analytical method based on (-)-hinokinin. For this purpose, an HPLC method was
developed using photo diode array detector and Waters HR C18 column with gradient elution
consisting of water and acetonitrile. The developed method was validated as per ICH-Q2B
guidelines and found to be accurate, precise and linear over a wide range of concentrations (5–
300 mg/mL). (-)-Hinokinin contents were found to be in the range of 0.005–0.109% (m/m) in
various P. cubeba samples. The developed method was extended to LC–MS for further
identiﬁcation and characterization of (-)-hinokinin in samples. The developed method is simple,
rapid and speciﬁc, and can be used as a tool for quality control of P. cubeba fruits and its
commercial formulations.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Piper cubeba (Fam.: Piperaceae), commonly known as cubeb
or tailed pepper, is a woody, climbing, perennial herb grown in
Indonesia mostly in Java and Sumatra islands. It is cultivated tosity. Production and hosting by Else
1
an Jiaotong University.
191882; fax: þ91 4027160512.
om (U.V. Mallavadhani).some extent in southern India [1]. Economically, P. cubeba is
important as a source of pepper (the dried berries) for the
worldwide spice market [2,3]. Its mature and dried fruits are the
ofﬁcial plant parts mentioned in the Indian Ayurvedic Pharmaco-
poeia under the name ‘Kankola’ and recommended for a variety of
ailments such as pain, tastelessness, painful urination and diseases
[4]. In Indonesian traditional medicine the berries of P. cubeba,
known as ‘kamukus’, are used to treat gonorrhea, dysentery,
syphilis, abdominal pain, diarrhea, enteritis and asthma [5,6].vier B.V. All rights reserved.
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of P. cubeba in order to prove its traditional use [6]. The methanol
and water extracts of P. cubeba berries have been shown to display
an inhibitory effect against the hepatitis C virus [7]. Anti-
inﬂammatory, antioxidant, antiallergic and analgesic activities of
P. cubeba have been studied using chemically induced edema and
arthritis in vivo [8,9]. Phytochemically P. cubeba has received less
attention in comparison to other species of the Piper genus. Only
three classes of secondary metabolites have been reported from the
berries of P. cubeba, i.e., alkaloids, lignans and terpenoids
(essential oil). The lignans and the essential oil have been more
intensively investigated, since P. cubeba accumulates both groups
of compounds in relatively high amounts. Twenty-four lignans
have so far been reported from P. cubeba [10–15]. Among these,
(-)-hinokinin, a dibenzylbutyrolactone lignan, is found to accumu-
late in signiﬁcant quantities. Furthermore, (-)-hinokinin was
reported to exhibit potent biological activities such as trypanoso-
micidal, anti-inﬂammatory and analgesic effects [8,9]. Owing to its
signiﬁcant accumulation and potent biological activities, (-)-hino-
kinin can be considered as the bio-active marker compound of P.
cubeba. For quality evaluation of P. cubeba fruits and their
commercial formulations, there is an urgent need to develop a
rapid, reliable and reproducible analytical method based on the
bio-active marker, (-)-hinokinin. High performance liquid chro-
matography–tandem mass spectrometry (HPLC–MS) has been
used successfully in recent years for the identiﬁcation and
quantitation of several herbal formulations [16,17]. HPLC pro-
vides speciﬁc, selective and sensitive quantitative results, often
with reduced sample preparation and analysis time when compared
to other techniques commonly employed. With this background,
we have now developed and validated a simple, rapid and sensitive
HPLC-PDA method for quantitative estimation of (-)-hinokinin
and ESI-MS was used for its identiﬁcation in single and multi-
herbal formulations containing P. cubeba.Fig. 1 Chemical structure of (-)-hinokinin.2. Experimental
2.1. Plant extract and commercial formulations
P. cubeba fruits were procured from local market (PCFI-1)
and from two reputed Ayurvedic pharmacies viz. M/s Shree
Dhootapapeshwar Pvt. Ltd., Mumbai, India (PCFI-2) and M/s
IMIS Pharmaceuticals Pvt. Ltd., Vijayawada, India (PCFI-3). The
commercial formulations of P. cubeba such as Khadiradi gutika
bulk powder (Batch no.: P 120800187) (PCFF-1) and Khadiradi
gutika tablet (Batch no.: P120600152) (PCFF-2) from M/s Shree
Dhootapapeshwar Pvt. Ltd., Mumbai, Ganaprabha tablet (PCFF-3),
Manasamitra gutika (PCFF-4) and Dhanwantari Gutika (PCFF-5)
from M/s IMIS Pharmaceuticals Pvt. Ltd., Vijayawada, India, were
procured.
2.2. Chemicals and solvents
HPLC grade acetonitrile was purchased from Fischer Scientiﬁc
(Thermo Electron LLS India Pvt. Ltd., Mumbai, India). Ultrapure
water was obtained from a MilliQ system (Millipore Corp.,
Bedford, MA, USA). Membrane ﬁlters F-450 (0.45 μm) were
obtained from Pall Gelman Laboratory Ltd. (Portsmouth, UK).
Sample tubes were obtained from Tarsons (Kolkata, India). A
centrifuge (model 2-16P) supplied by Sigma (Zurich, Switzerland)
was used.2.3. Isolation of (-)-hinokinin
The fruits of P. cubeba were powdered in a pulverizer and the
powdered material (285 g) was extracted with methanol (1000 mL)
in a soxhlet extractor under hot conditions for 12 h. The resultant
methanol solubles on concentration under reduced pressure
afforded the methanol extract (33 g). Column chromatographic
puriﬁcation of the methanol extract (10 g) on the silica gel column
using the gradient elution of hexane and ethyl acetate resulted in
several fractions. Based on thin layer chromatography, one of the
fractions (hexane:ethyl acetate: 70:30) was taken up for further
chromatographic puriﬁcation and a colorless semi-solid isolated
(250 mg), Rf 0.45 (hexane:ethyl acetate: 70:30), ESI-MS (þve
mode): 355.1, IR (KBr, √max): 1780 (lactone), 1H NMR
(400 MHz, CDCl3): 2.45 (m, 1H, H-3), 2.60 (m, 1H, H-2), 2.48
and 2.80 (2m, each 1H, α0-H2), 2.84 and 3.0 (2m, each 1H,
α-H2), 3.86 and 4.12 (2m, each 1H, H-1), 5.94 (s, 4H, 2
CH2O2), 6.44 6.76 (m, 6H, 2Ar–H), 13C NMR (400 MHz,
CDCl3): 178.33 (C1), 147.88 (C30, C3″), 146.49 (C40, C4″), 131.56
(C10), 131.28 (C1″), 122.20 (C60), 121.51 (C6″), 109.40 (C2″),
108.78 (C20), 108.33 (C50), 108.25 (C5″), 101.00 (–CH2O2), 71.13
(C4), 46.47 (C2), 41.26 (C3), 38.34 (α0), 34.81 (α″). Based on the
above spectral data and comparison with reported values [18], the
compound was identiﬁed as (-)-hinokinin {(2R, 3R)-2,3-di-(3,4-
methylenedioxybenzyl)-butyrolactone} (Fig. 1).
2.4. Preparation of reference standard
Reference standard solution of marker compound, (-)-hinokinin,
was prepared by dissolving 5 mg in 5 mL of acetonitrile. Calibra-
tion standards ranging from 5 to 300 mg/mL were subsequently
prepared by diluting with water:acetonitrile (50:50).
2.5. Preparation of samples
The methanolic extracts of P. cubeba fruit ingredient ((PCFI-1,
PCFI-2 and PCFI-3) and the commercial formulations (PCFF-1 to
PCFF-5) were prepared for the quantiﬁcation of (-)-hinokinin. The
test samples (5.0 g) were extracted with methanol (5 20 mL) in a
sonicator bath at 3500 rpm for 30 min following the optimized
protocols. The supernatants were collected, ﬁltered and evaporated
to dryness under reduced pressure and the samples were recon-
stituted using mobile phase (water:acetonitrile: 50:50, v/v) and
then ﬁltered using membrane ﬁlters of 0.45 μm pore size.
2.6. HPLC conditions
Chromatographic separation was achieved by reverse-phase
chromatography using the gradient elution. Chromatography
K. Haribabu et al.132was performed on Waters HRC18 (300 mm 3.9 mm i.d., 6 μm
particle size) (Waters, India) column. The mobile phase consisted
of water as component A and acetonitrile as component B. A
gradient elution program was used: from 0 min: 40%, B; 25.0 min:
60% B; 40.0 min: 70% B; 45 min: 70% B; 46.0 min: 40% B; 60.0
min stop time: 40% B; ﬂow rate 1.0 mL/min was used. The
chromatogram was monitored at 288 nm and UV spectra of
individual peaks were recorded in the range of 200–400 nm.
Chromatographic separation was performed using HPLC equipped
with a degasser (G1379A), binary pump (G1312A), autosampler
(G1329A), autosampler thermostat (G1329B) and diode array
detector (G1315B) of Agilent Technologies 1100 series (Ger-
many). The sample injection volume was 20 μL and the column
temperature was maintained at ambient conditions (2371 1C). The
data were acquired and processed using Chemstation.
2.7. MS conditions
Identiﬁcation of the markers was carried out using ion trap mass
spectrometer and MS analysis was carried out in positive mode
using electrospray ionization (ESI). Nitrogen was used as the
nebulizer and curtain gas. The ion source conditions were set as
follows: temperature, 335 1C; nebulizer gas, 220.6 kPa; dry gas,
10.0 L/min; ion spray voltage, 5000 V; collision energy, 33.0 V;
electron multiplier voltage, 2100 V; declusturing potential, 54 V;
focusing potential, 400 V; entrance potential, 10 V; collision exit
potential, 27 V; and dwell time, 200 ms. LC/MSD trap software
4.2 (Bruker, Waldbronn, Germany) was used for mass
spectrometer.
2.8. Method validation
Method validation including system suitability, speciﬁcity, linear-
ity, LOD, LOQ, precision, accuracy, recovery and stability was
carried out as per ICH-Q2B guidance [19].
2.8.1. System suitability
The system suitability parameters including capacity factor (K0),
resolution (Rs), theoretical plates (N), height equivalent to
theoretical plates (HETP) and asymmetry (As) were evaluated
for the developed method.
2.8.2. Speciﬁcity
The peak purity results obtained from the diode array detector
under the optimized chromagraphic conditions conﬁrmed that
peaks corresponding to markers were homogenous and not co-
eluting with peaks that correspond to any other compound.
2.8.3. Linearity and calibration curve
Linearity of (-)-hinokinin was determined with seven concentra-
tion levels over the range of 5–300 μg/mL. The calibration curve
was established by plotting the peak area (Y-axis) against
concentration (X-axis) of the calibration solutions with linear
regression analysis. Calibration curves showed that there was a
linear correlation between peak area and concentration of standard
solution. Linear regression analysis was followed and the correla-
tion of coefﬁcient (r2) was used as a measure of linearity.
2.8.4. LOD and LOQ
The limits of detection and quantiﬁcation for each compound were
determined by the signal-to-noise (S/N) ratio for (-)-hinokinin.LOD was calculated as the amount of the injected sample given a
signal to noise ratio of 3, and LOQ was determined when the S/N
ratio was 10.
2.8.5. Precision and accuracy
Precision (intra- and inter-day) and repeatability were carried out
on the P. cubeba samples. Percentage relative standard deviation
(% RSD) was considered as a measure of precision and repeat-
ability. The P. cubeba samples were prepared and analyzed
for (-)-hinokinin concentration on the same day (n¼15) and on
three consecutive days (n¼5) for intra- and inter-day precision,
respectively. For repeatability, the P. cubeba samples were
prepared on three different days and analyzed for (-)-hinokinin
content (n¼5). The accuracy of the method was determined by %
accuracy of (-)-hinokinin obtained from the P. cubeba samples.
2.8.6. Recovery
Recovery of the method was studied using a standard addition
method. (-)-Hinokinin (at 100% concentration level) was added to
PCFI-1 and the sample was processed as per sample preparation
method described in Section 2. Mean percentage (%) recovery of
PCFI-1 was used as a measure of accuracy and was calculated
using the following formula: percentage recovery¼ (amount
detected 100/theoretical amount).
2.8.7. Stability
The stability of the analyte was tested for 24 h at room temperature
(2571 1C) and refrigerator temperature (4 1C). The peak area of
the freshly prepared (-)-hinokinin standard solution (100 μg/mL)
was compared with the stability samples at different temperatures
collected at different time intervals.3. Results and discussion
It has been realized internationally that marker compound based on
standardization of herbal drugs is the most reliable quality control
tool for providing consistent and efﬁcacious herbal formulations
[20–24]. In the present study, a similar approach was used to
standardize the traditionally important herbal medicine, P. cubeba,
using the HPLC method. The chromatographic conditions with
respect to mobile phase, gradient elution and column were
optimized based on peak shape, response and peak resolution of
(-)-hinokinin. The gradient elution of the mobile phase was used
for the best resolution in the crude extracts and herbal formulations
(Fig. 2).
The mass spectrometer with an electrospray ion source (ESI)
interface was used for MS analysis. The MS spectra of (-)-hino-
kinin exhibited the ions m/z 377[MþNa]þ, 355 [MþH]þ, 337,
319, 173, 135. The possible fragmentation pattern of (-)-hinokinin
is illustrated in Fig. 3. Similar mass fragmentation pattern was
observed in samples for (-)-hinokinin (Fig. 4).
3.1. Method validation
The analytical method was validated to meet the acceptance
criteria as per International Conference on Harmonization of
technical requirements for registration of pharmaceuticals for
human use (ICH) guidelines.
System suitability tests were used to verify whether the system
is adequate for the analysis to be performed, and the parameters for
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Fig. 3 Possible MS fragmentation pattern of (-)-hinokinin.
Fig. 2 HPLC-DAD proﬁles of (A) (-)-hinokinin; (B) PCFI-1; (C) PCFI-2; (D) PCFI- 3; (E) PCFF-1; (F) PCFF-2; (G) PCFF-3; (H) PCFF-4; (I) PCFF-5.
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Fig. 4 Mass spectra of (A) (-)-hinokinin; (B) PCFI-1; (C) PCFI-2; (D) PCFI-3; (E) PCFF-1; (F) PCFF-2; (G) PCFF-3; (H) PCFF-4; (I) PCFF-5.
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matographic system are given in Table 1.
The retention time of (-)-hinokinin (17.6070.10 min) in the standard
and samples was the same and the UV spectra of (-)-hinokinin in
samples were similar to those in standard (-)-hinokinin (Fig. 5). This
emphasizes that the developed method was speciﬁcally for (-)-hinokinin.Seven different concentrations ranging from 5 to 300 μg/mL
were used for the calibration plot. The method showed excellent
linearity (r2, 0.999) with the regression equation y¼66.718x
57.958 in the above concentration range.
The LOD and LOQ for (-)-hinokinin were found to be 0.8 mg/mL
and 2.5 mg/mL, respectively.
Quantitative estimation of (-)-hinokinin using HPLC-PDA 135The P. cubeba sample was used for the determination of
intra- and inter-day precision and accuracy. The % RSD values
for precision of (-)-hinokinin were found to be in the range of
0.058–0.593% and 0.094–1.005%, respectively (Table 2). The
intra- and inter-day accuracy of (-)-hinokinin was found to be in
the range of 99.86–100.04% and 99.71–100.00%, respectively
(Table 2)Table 1 System suitability parameters.
Parameter Values
Resolution (R) 2.27
Capacity factor (K0) 2.13
Theoretical plates (N) 4527
HETP (H) 0.091
Asymmetry (As) 1.02
Fig. 5 Overlaid UV spectra of standard (-)-hinokinin and samples.
Table 3 The recovery of hinokinin from spiked samples (n¼6).
Sample code Initial amount Added amount
(μg) (μg)
PCFI-1 84.98 30
84.98 15
84.98 5
PCFI-2 109.00 30
109.00 15
109.00 5
PCFI-3 7.80 30
7.80 15
7.80 5
Table 2 Results of precision and accuracy (n¼5).
Sample no. Concentration (μg/mL) Intra-day
Accuracy (%)
1 10 99.86
2 50 100.04
3 100 100.00The data on recovery were obtained by spiking
known concentrations of standard (-)-hinokinin in the
low, medium and higher ranges (5, 15, 30 μg/mL, respectively)
of the P. cubeba. Mean recovery for (-)-hinokinin was found to be
97.21–99.43% (Table 3).
(-)-Hinokinin was found to be stable for 24 h at room
temperature and refrigerator temperature against the freshly pre-
pared (-)-hinokinin standard solution (100 μg/mL).
3.2. Method applicability
The validated method was applied for quantitative determination
of (-)-hinokinin in various traditional Ayurvedic and herbal com-
mercial formulations (Table 4). The (-)-hinokinin content was found
to be in the range of 0.005–0.109% (m/m) with the high- and
low-yielding samples being PCFI-2 and PCFF-4, respectively. The
(-)- hinokinin content in the ingredients PCFI-1 and PCFI-2 is
almost comparable, whereas it is tenfold less in the ingredient PCFI-
3. It could be mentioned here that the ﬁrst two samples used are raw
fruits, while the third one is a processed fruit powder. It is a general
observation that the fresh raw plant ingredients yield more
extractives than the stored powdered materials. This may be the
reason for the low yield of (-)-hinokinin in the third ingredient. In
case of Khadiradi gutika formulation, the powder form (PCFF-1)
gave more (-)-hinokinin content (0.040%) than the tablet form
(PCFF-2) (0.006%). In case of tablets, the ingredients are adhered
strongly to binders and excipients, for which the (-)-hinokinin
content in tablets was found to be low. In case of other formula-
tions, the (-)-hinokinin content is proportional to the number of
ingredients used in each formulation. In conclusion, a new, simple,
rapid and sensitive HPLC–MS method has been developed and
validated for quantitative estimation of (-)-hinokinin in P. cubeba
fruit and its commercial formulations. The developed method can be
used as a quality control tool for maintaining the quality of rawDetected amount Recovery (%) Mean recovery
(μg) 7RSD (%)
112.95 98.24 97.2171.22
97.49 97.51
86.29 95.91
138.98 99.99 98.8671.08
121.33 97.85
112.57 98.75
38.49 101.85 99.4372.12
22.45 98.50
12.53 97.95
Inter-day
RSD (%) Accuracy (%) RSD (%)
0.593 99.71 1.005
0.235 100.00 0.244
0.058 99.96 0.094
Table 4 Accumulation of hinokinin in various P. cubeba samples.
Sample no. Sample ID Retention time (min) Quantity (m/m, %) (RSD)
1 PCFI-1 17.60 0.084 (1.224)
2 PCFI-2 17.60 0.109 (1.082)
3 PCFI-3 17.60 0.008 (2.122)
4 PCFF-1 17.70 0.040 (0.245)
5 PCFF-2 17.64 0.006 (1.250)
6 PCFF-3 17.50 0.020 (0.445)
7 PCFF-4 17.70 0.005 (1.105)
8 PCFF-5 17.60 0.011 (0.532)
K. Haribabu et al.136plant material, which is very essential for maintaining the claimed
therapeutic activity of the P. cubeba formulations.
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